Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$14.72 USD
-0.30 (-2.00%)
Updated May 3, 2024 04:00 PM ET
After-Market: $14.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Catalyst Pharmaceuticals, Inc. [CPRX]
Reports for Purchase
Showing records 121 - 140 ( 417 total )
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
LEMS Geographic Expansion Strategy Matched With Coordinated Litigation Efforts; Reit Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q20 Recap - Discounted Valuation with Cash Generation
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Barbarians at the Gate; Our Thoughts on the Ongoing Defense of Firdapse IP Protection in LEMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse Development and the Band Plays On, Despite Failure in MuSK-MG Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q20 Recap - Pipeline Snag, but Valuation Still Compelling
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Musings on LEMS Landscape as FDA Litigation Decision Expected 3Q20; Reit Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department